Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-275183 in pretreated NSCLC
NCT00359450Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2006
- Primary completion
- Mar 2007
- Modality
- Allosteric Modulators
- Countries
- 8
01
Overview
A Phase 2 trial of bms-275183 in non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Started Jul 2006; status: terminated.
02
Drugs
bms-275183
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00359450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00359450.